List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1801674/publications.pdf Version: 2024-02-01



KEVIN FONE

#	Article	IF	CITATIONS
1	Dopaminergic neuromodulation of prefrontal cortex activity requires the NMDA receptor coagonist <scp>d</scp> -serine. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	14
2	Comparative Pro-cognitive and Neurochemical Profiles of Glycine Modulatory Site Agonists and Glycine Reuptake Inhibitors in the Rat: Potential Relevance to Cognitive Dysfunction and Its Management. Molecular Neurobiology, 2020, 57, 2144-2166.	4.0	17
3	Oxytocin attenuates phencyclidine hyperactivity and increases social interaction and nucleus accumben dopamine release in rats. Neuropsychopharmacology, 2019, 44, 295-305.	5.4	44
4	Post-weaning social isolation of rats leads to long-term disruption of the gut microbiota-immune-brain axis. Brain, Behavior, and Immunity, 2018, 68, 261-273.	4.1	97
5	Role of the anterior cingulate cortex in the retrieval of novel object recognition memory after a long delay. Learning and Memory, 2017, 24, 310-317.	1.3	22
6	Infections Up to 76ÂDays After Stroke Increase Disability and Death. Translational Stroke Research, 2017, 8, 541-548.	4.2	25
7	Contribution of serotonin and dopamine to changes in core body temperature and locomotor activity in rats following repeated administration of mephedrone. Addiction Biology, 2016, 21, 1127-1139.	2.6	33
8	Down-Regulation of Hippocampal Genes Regulating Dopaminergic, GABAergic, and Glutamatergic Function Following Combined Neonatal Phencyclidine and Post-Weaning Social Isolation of Rats as a Neurodevelopmental Model for Schizophrenia. International Journal of Neuropsychopharmacology, 2016, 19, pyw062.	2.1	27
9	The dopamine D 3 -preferring D 2 /D 3 dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia. European Neuropsychopharmacology, 2016, 26, 208-224.	0.7	49
10	Dopamine D1 receptor stimulation modulates the formation and retrieval of novel object recognition memory: Role of the prelimbic cortex. European Neuropsychopharmacology, 2015, 25, 2145-2156.	0.7	43
11	Too Little and Too Much: Hypoactivation and Disinhibition of Medial Prefrontal Cortex Cause Attentional Deficits. Journal of Neuroscience, 2014, 34, 7931-7946.	3.6	96
12	In Vivo Neurometabolic Profiling to Characterize the Effects of Social Isolation and Ketamine-Induced NMDA Antagonism: A Rodent Study at 7.0 T. Schizophrenia Bulletin, 2014, 40, 566-574.	4.3	28
13	Negative symptoms of schizophrenia: Clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment. European Neuropsychopharmacology, 2014, 24, 645-692.	0.7	255
14	Neonatal phencyclidine administration and post-weaning social isolation as a dual-hit model of â€~schizophrenia-like' behaviour in the rat. Psychopharmacology, 2014, 231, 2533-2545.	3.1	39
15	The preclinical pharmacology of mephedrone; not just <scp>MDMA</scp> by another name. British Journal of Pharmacology, 2014, 171, 2251-2268.	5.4	61
16	D-Amphetamine and Antipsychotic Drug Effects on Latent Inhibition in Mice Lacking Dopamine D2 Receptors. Neuropsychopharmacology, 2013, 38, 1512-1520.	5.4	18
17	The atypical antipsychotic risperidone reverses the recognition memory deficits induced by post-weaning social isolation in rats. Psychopharmacology, 2013, 228, 31-42.	3.1	31
18	Behavioural and neurochemical comparison of chronic intermittent cathinone, mephedrone and MDMA administration to the rat. European Neuropsychopharmacology, 2013, 23, 1085-1095.	0.7	73

#	Article	IF	CITATIONS
19	Differential effects of cathinone compounds and <scp>MDMA</scp> on body temperature in the rat, and pharmacological characterization of mephedroneâ€induced hypothermia. British Journal of Pharmacology, 2013, 168, 966-977.	5.4	43
20	Selective Blockade of Dopamine D3 Receptors Enhances while D2 Receptor Antagonism Impairs Social Novelty Discrimination and Novel Object Recognition in Rats: A Key Role for the Prefrontal Cortex. Neuropsychopharmacology, 2012, 37, 770-786.	5.4	138
21	S32212, a Novel Serotonin Type 2C Receptor Inverse Agonist/α ₂ -Adrenoceptor Antagonist and Potential Antidepressant: II. A Behavioral, Neurochemical, and Electrophysiological Characterization. Journal of Pharmacology and Experimental Therapeutics, 2012, 340, 765-780.	2.5	27
22	Blockade of dopamine D3 but not D2 receptors reverses the novel object discrimination impairment produced by post-weaning social isolation: implications for schizophrenia and its treatment. International Journal of Neuropsychopharmacology, 2012, 15, 471-484.	2.1	68
23	5â€HT ₆ receptor agonists and antagonists enhance learning and memory in a conditioned emotion response paradigm by modulation of cholinergic and glutamatergic mechanisms. British Journal of Pharmacology, 2012, 167, 436-449.	5.4	84
24	Lost in translation: preclinical studies on 3,4â€methylenedioxymethamphetamine provide information on mechanisms of action, but do not allow accurate prediction of adverse events in humans. British Journal of Pharmacology, 2012, 166, 1523-1536.	5.4	51
25	5â€HT ₆ receptor recruitment of mTOR as a mechanism for perturbed cognition in schizophrenia. EMBO Molecular Medicine, 2012, 4, 1043-1056.	6.9	152
26	Fos expression in the prefrontal cortex and ventral striatum after exposure to a free-operant timing schedule. Behavioural Brain Research, 2012, 235, 273-279.	2.2	4
27	Exposure to maternal consumption of cafeteria diet during the lactation period programmes feeding behaviour in the rat. International Journal of Developmental Neuroscience, 2011, 29, 785-793.	1.6	55
28	Influence of social isolation in the rat on serotonergic function and memory – Relevance to models of schizophrenia and the role Âof 5-HT6 receptors. Neuropharmacology, 2011, 61, 400-407.	4.1	73
29	Translational neuropharmacology and the appropriate and effective use of animal models. British Journal of Pharmacology, 2011, 164, 1041-1043.	5.4	17
30	Animal models of schizophrenia. British Journal of Pharmacology, 2011, 164, 1162-1194.	5.4	613
31	E-6801, a 5-HT6 receptor agonist, improves recognition memory by combined modulation of cholinergic and glutamatergic neurotransmission in the rat. Psychopharmacology, 2011, 213, 413-430.	3.1	85
32	Acute concomitant effects of MDMA binge dosing on extracellular 5-HT, locomotion and body temperature and the long-term effect on novel object discrimination in rats. Psychopharmacology, 2011, 213, 365-376.	3.1	35
33	The mGluR2/3 agonist LY379268 reverses post-weaning social isolation-induced recognition memory deficits in the rat. Psychopharmacology, 2011, 214, 269-283.	3.1	74
34	Phencyclidine withdrawal disrupts episodic-like memory in rats: reversal by donepezil but not clozapine. International Journal of Neuropsychopharmacology, 2010, 13, 1011-1020.	2.1	15
35	Comparison of the effects of 2,5-dimethoxy-4-iodoamphetamine and D-amphetamine on the ability of rats to discriminate the durations and intensities of light stimuli. Behavioural Pharmacology, 2010, 21, 11-20.	1.7	17
36	The dopamine D3 receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures. International Journal of Neuropsychopharmacology, 2010, 13, 1035-1051.	2.1	70

#	Article	IF	CITATIONS
37	Impact of regional 5-HT depletion on the cognitive enhancing effects of a typical 5-ht6 receptor antagonist, Ro 04-6790, in the Novel Object Discrimination task. Psychopharmacology, 2009, 202, 111-123.	3.1	28
38	MDMA: On the translation from rodent to human dosing. Psychopharmacology, 2009, 204, 375-378.	3.1	50
39	Fluoxetine administration modulates the cytoskeletal microtubular system in the rat hippocampus. Synapse, 2009, 63, 359-364.	1.2	49
40	Increased dopamine D receptors in rats reared in social isolation. Synapse, 2009, 63, 476-483.	1.2	64
41	Mapping the central effects of methylphenidate in the rat using pharmacological MRI BOLD contrast. Neuropharmacology, 2009, 57, 653-664.	4.1	15
42	Effects of social isolation rearing on the limbic brain: A combined behavioral and magnetic resonance imaging volumetry study in rats. Neuroscience, 2009, 159, 21-30.	2.3	93
43	Chronic fluoxetine differentially modulates the hippocampal microtubular and serotonergic system in grouped and isolation reared rats. European Neuropsychopharmacology, 2009, 19, 778-790.	0.7	25
44	Behavioural and neurochemical effects of post-weaning social isolation in rodents—Relevance to developmental neuropsychiatric disorders. Neuroscience and Biobehavioral Reviews, 2008, 32, 1087-1102.	6.1	752
45	An update on the role of the 5-hydroxytryptamine6 receptor in cognitive function. Neuropharmacology, 2008, 55, 1015-1022.	4.1	125
46	A role for the 5-HT1A, 5-HT4 and 5-HT6 receptors in learning and memory. Trends in Pharmacological Sciences, 2008, 29, 482-492.	8.7	266
47	Depletion of 26S Proteasomes in Mouse Brain Neurons Causes Neurodegeneration and Lewy-Like Inclusions Resembling Human Pale Bodies. Journal of Neuroscience, 2008, 28, 8189-8198.	3.6	290
48	Effects of amphetamine isomers, methylphenidate and atomoxetine on synaptosomal and synaptic vesicle accumulation and release of dopamine and noradrenaline in vitro in the rat brain. Neuropharmacology, 2007, 52, 405-414.	4.1	83
49	Atomoxetine produces changes in cortico-basal thalamic loop circuits: Assessed by phMRI BOLD contrast. Neuropharmacology, 2007, 52, 812-826.	4.1	36
50	Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 2007, 21, 10-41.	4.0	232
51	Differential effects of the d- and l- isomers of amphetamine on pharmacological MRI BOLD contrast in the rat. Psychopharmacology, 2007, 193, 11-30.	3.1	20
52	Evidence for the sensitivity of operant timing behaviour to stimulation of D1 dopamine receptors. Psychopharmacology, 2007, 195, 213-222.	3.1	17
53	Effects of 5-HT1A and 5-HT2A receptor stimulation on temporal differentiation performance in the fixed-interval peak procedure. Behavioural Processes, 2006, 71, 250-257.	1.1	23
54	Evidence that the effect of 5-HT2 receptor stimulation on temporal differentiation is not mediated by receptors in the dorsal striatum. Behavioural Processes, 2006, 71, 258-267.	1.1	16

#	Article	IF	CITATIONS
55	Effects of 5-HT2A receptor stimulation on the discrimination of durations by rats. Behavioural Pharmacology, 2006, 17, 51-59.	1.7	24
56	Isolation rearing induces recognition memory deficits accompanied by cytoskeletal alterations in rat hippocampus. European Journal of Neuroscience, 2006, 24, 2894-2902.	2.6	162
57	Evidence for a role of D1 dopamine receptors in d-amphetamine's effect on timing behaviour in the free-operant psychophysical procedure. Psychopharmacology, 2006, 185, 378-388.	3.1	25
58	Guanfacine produces differential effects in frontal cortex compared with striatum: assessed by phMRI BOLD contrast. Psychopharmacology, 2006, 189, 369-385.	3.1	36
59	Effects of d-amphetamine and DOI (2,5-dimethoxy-4-iodoamphetamine) on timing behavior: interaction between D1 and 5-HT2A receptors. Psychopharmacology, 2006, 189, 331-343.	3.1	26
60	Long-lasting changes in behavioural and neuroendocrine indices in the rat following neonatal maternal separation: Gender-dependent effects. Brain Research, 2006, 1097, 123-132.	2.2	159
61	Involvement of 5-HT2C Receptors in the Regulation of Food Intake in Siberian Hamsters. Journal of Neuroendocrinology, 2005, 17, 276-285.	2.6	14
62	Effects of quipazine and m-chlorophenylbiguanide (m-CPBG) on temporal differentiation: evidence for the involvement of 5-HT2A but not 5-HT3 receptors in interval timing behaviour. Psychopharmacology, 2005, 181, 289-298.	3.1	16
63	Behavioural and pharmacological magnetic resonance imaging assessment of the effects of methylphenidate in a potential new rat model of attention deficit hyperactivity disorder. Psychopharmacology, 2005, 180, 716-723.	3.1	17
64	Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder. Current Opinion in Pharmacology, 2005, 5, 87-93.	3.5	106
65	Genetic knockout and pharmacological blockade studies of the 5-HT7 receptor suggest therapeutic potential in depression. Neuropharmacology, 2005, 48, 492-502.	4.1	199
66	5-ht6 Receptors. CNS and Neurological Disorders, 2004, 3, 59-79.	4.3	249
67	Effects of coadministration of cannabinoids and morphine on nociceptive behaviour, brain monoamines and HPA axis activity in a rat model of persistent pain. European Journal of Neuroscience, 2004, 19, 678-686.	2.6	67
68	Decreased social behaviour following 3,4-methylenedioxymethamphetamine (MDMA) is accompanied by changes in 5-HT2A receptor responsivity. Neuropharmacology, 2004, 46, 202-210.	4.1	60
69	5-HT6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation—an effect sensitive to NMDA receptor antagonism. Neuropharmacology, 2004, 47, 195-204.	4.1	191
70	Reversal of a cholinergic-induced deficit in a rodent model of recognition memory by the selective 5-HT6 receptor antagonist, Ro�04-6790. Psychopharmacology, 2003, 170, 358-367.	3.1	119
71	Implantation of a Slow Release Corticosterone Pellet Induces Longâ€Term Alterations in Serotonergic Neurochemistry in the Rat Brain. Journal of Neuroendocrinology, 2003, 15, 607-613.	2.6	28
72	Reduced social interaction following 3,4-methylenedioxymethamphetamine is not associated with enhanced 5-HT2C receptor responsivity. Neuropharmacology, 2003, 44, 439-448.	4.1	42

#	Article	IF	CITATIONS
73	The hypothermic effect of 5-CT in mice is mediated through the 5-HT7 receptor. Neuropharmacology, 2003, 44, 1031-1037.	4.1	92
74	DR4004, a putative 5-HT7 receptor antagonist, also has functional activity at the dopamine D2 receptor. European Journal of Pharmacology, 2002, 449, 105-111.	3.5	17
75	Alteration in 5-hydroxytryptamine agonist-induced behaviour following a corticosterone implant in adult rats. Pharmacology Biochemistry and Behavior, 2002, 71, 815-823.	2.9	9
76	Long-term changes in social interaction and reward following repeated MDMA administration to adolescent rats without accompanying serotonergic neurotoxicity. Psychopharmacology, 2002, 159, 437-444.	3.1	92
77	A role for 5-ht6 receptors in retention of spatial learning in the Morris water maze. Neuropharmacology, 2001, 41, 210-219.	4.1	196
78	Effect of repeated methylphenidate administration on presynaptic dopamine and behaviour in young adult rats. Journal of Psychopharmacology, 2001, 15, 67-75.	4.0	35
79	Immunohistochemical localisation of the 5-HT2C receptor protein in the rat CNS. Neuropharmacology, 2000, 39, 123-132.	4.1	340
80	Investigation of stretching behaviour induced by the selective 5-HT6 receptor antagonist, Ro 04-6790, in rats. British Journal of Pharmacology, 1999, 126, 1537-1542.	5.4	95
81	Pindolol-insensitive [3 H]-5-hydroxytryptamine binding in the rat hypothalamus; identity with 5-hydroxytryptamine7 receptors. British Journal of Pharmacology, 1999, 127, 236-242.	5.4	18
82	Modification of 5-HT2 receptor mediated behaviour in the rat by oleamide and the role of cannabinoid receptors. Neuropharmacology, 1999, 38, 533-541.	4.1	115
83	Effect of chronic m -CPP on locomotion, hypophagia, plasma corticosterone and 5-HT2C receptor levels in the rat. British Journal of Pharmacology, 1998, 123, 1707-1715.	5.4	60
84	Activation of 5-HT 2B Receptors in the Medial Amygdala causes Anxiolysis in the Social Interaction Test in the Rat. Neuropharmacology, 1997, 36, 601-608.	4.1	84
85	Evidence for expression of the 5-hydroxytryptamine-2B receptor protein in the rat central nervous system. Neuroscience, 1997, 76, 323-329.	2.3	199
86	Effect of neuropeptides on cognitive function. Experimental Gerontology, 1997, 32, 451-469.	2.8	74
87	Increased 5-HT2C receptor responsiveness occurs on rearing rats in social isolation. Psychopharmacology, 1996, 123, 346-352.	3.1	118
88	The serotoninergic bulbospinal system and brainstern-spinal cord content of serotonin-, TRH-, and substance P-like immunoreactivity in the aged rat with special reference to the spinal cord motor nucleus. Synapse, 1993, 15, 63-89.	1.2	60
89	Galanin fails to alter both acquisition of a two trial per day water maze task and neurochemical markers of cholinergic or serotonergic neurones in adult rats. Brain Research, 1993, 622, 330-336.	2.2	14
90	Thyrotropin-releasing hormone (TRH)-like immunoreactivity in the grey monkey (Macaca fascicularis) spinal cord and medulla oblongata with special emphasis on the bulbospinal tract. Journal of Comparative Neurology, 1992, 322, 293-310.	1.6	14

#	Article	IF	CITATIONS
91	Characterization of the 5â€HT receptor subtypes involved in the motor behaviours produced by intrathecal administration of 5â€HT agonists in rats. British Journal of Pharmacology, 1991, 103, 1547-1555.	5.4	63
92	5-Hydroxytryptamine, substance P, and thyrotropin-releasing hormone in the adult cat spinal cord segment L7: Immunohistochemical and chemical studies. Synapse, 1990, 6, 237-270.	1.2	79
93	Involvement of 5â€HT ₂ receptors in the behaviours produced by intrathecal administration of selected 5â€HT agonists and the TRH analogue (CG 3509) to rats. British Journal of Pharmacology, 1989, 96, 599-608.	5.4	60
94	Involvement of catecholaminergic neurones and α-adrenoceptors in the Wet-dog shake and forepaw licking behaviour produced by the intrathecal injection of an analogue of thyrotrophin-releasing hormone (CG 3509). Neuropharmacology, 1987, 26, 1147-1155.	4.1	34
95	Regional Distribution of Substance P- and Thyrotrophin-Releasing Hormone-Like Immunoreactivity and Indoleamines in the Rabbit Spinal Cord. Journal of Neurochemistry, 1987, 48, 1027-1032.	3.9	28